SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris reported Q2 2026 results with a loss per share of €0.70,…

Pharvaris N.V. · PRESS-RELEASE filed Aug 12, 2026 at 06:50 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Aug 12, 2026 at 06:50 ET

Pharvaris reported Q2 2026 results with a loss per share of €0.70, slightly above the consensus EPS estimate of -$0.65 (per ADS) but the comparison is not directly comparable due to currency and share basis differences. The key event is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, which is the primary stock-moving catalyst.

  • Cash and cash equivalents of €318 million as of June 30, 2026, extending cash runway into 2028
  • Loss for Q2 2026 was €47.8 million, or €0.70 per share, vs €45.5 million (€0.83 per share) in Q2 2025
  • Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026
  • FDA accepted NDA for deucrictibant IR with PDUFA date of April 23, 2027; EMA validated MAA in July 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access